<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340024</url>
  </required_header>
  <id_info>
    <org_study_id>2003/419/B</org_study_id>
    <nct_id>NCT04340024</nct_id>
  </id_info>
  <brief_title>Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients</brief_title>
  <official_title>Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke-NUS Graduate Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ImmunoSCAPE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Decipher Biosciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have
      experienced severe acute/ late side effects to radiotherapy will be recruited to the study.
      Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue
      samples will be processed and studied for genetic and biochemical markers that have potential
      to be used for predicting sensitivity to radiation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples</measure>
    <time_frame>Blood is taken at informed consent; tissue is from archived sample</time_frame>
    <description>Whole exome sequencing, single nucleotide polymorphism (SNP) assays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in immune profile of blood and tissue after radiation</measure>
    <time_frame>Blood is taken at informed consent; tissue is from archived sample</time_frame>
    <description>Mass cytometry using CyTOF technology will be used to detect the immune cell population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify proteins that are associated with radiation sensitivity in tissue samples</measure>
    <time_frame>Tissue is from archived sample</time_frame>
    <description>Immunohistochemistry will be used to detect protein expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify RNA expression pathways that are associated with radiation sensitivity in blood and tissue samples</measure>
    <time_frame>Blood is taken at informed consent; tissue is from archived sample</time_frame>
    <description>RNA sequencing</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Radiotherapy Side Effect</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      20mL of blood will be collected up to 5 times over 5 years
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from patients of the study team when they attend their
        regular clinic visits or when they are admitted to the hospital. These are patients from
        NCCS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe side effects from radiotherapy

          -  Patients with a type of cancer that is associated with sensitivity to radiotherapy

        Exclusion Criteria:

          -  Age of patient must be between 21 (inclusive) and 99 (exclusive)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melvin Chua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melvin Chua, MD</last_name>
    <email>melvin.chua.l.k@singhealth.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enya Ong</last_name>
    <phone>+65 6436 8000</phone>
    <email>enya.ong.h.w@nccs.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169690</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

